



Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, September 28, 2017 1:00 pm – 5:00 pm
Barbara Roberts Human Services Building, Room 137 A-D
500 Summer St. SE
Salem, OR 97301

MEETING AGENDA

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 as required by 414.325(9).

I. CALL TO ORDER

- | | | |
|---------|--|--|
| 1:00 PM | <ul style="list-style-type: none"> A. Roll Call & Introductions B. Conflict of Interest Declaration C. Approval of Agenda and Minutes D. Department Update | <ul style="list-style-type: none"> R. Citron (OSU) R. Citron (OSU) B. Origer (Chair) D. Weston (OHA) |
|---------|--|--|

II. DUR ACTIVITIES

- | | | |
|---------|--|---|
| 1:10 PM | <ul style="list-style-type: none"> A. Quarterly Utilization Reports B. ProDUR Report C. RetroDUR Report D. Oregon State Drug Reviews <ul style="list-style-type: none"> 1. New Biologics for Treatment of Moderate to Severe Psoriasis 2. Updates in the Management of COPD | <ul style="list-style-type: none"> R. Citron (OSU) R. Holsapple (DXC) D. Engen (OSU) K. Sentena (OSU) |
|---------|--|---|

III. DUR OLD BUSINESS

- | | | |
|---------|--|--|
| 1:20 PM | <ul style="list-style-type: none"> A. Low-dose Quetiapine <ul style="list-style-type: none"> 1. Removal of Prior Authorization Criteria 2. Public Comment 3. Discussion of Clinical Recommendations to OHA B. Hydroxyzine HCl <ul style="list-style-type: none"> 1. Removal of Prior Authorization Criteria 2. Public Comment 3. Discussion of Clinical Recommendations to OHA | <ul style="list-style-type: none"> S. Servid (OSU) S. Servid (OSU) |
|---------|--|--|

- C. Biologics for Autoimmune Conditions
 - 1. Update Prior Authorization Criteria
 - 2. Public Comment
 - 3. Discussion of Clinical Recommendations to OHA
- D. Moretz (OSU)

IV. PREFERRED DRUG LIST NEW BUSINESS

- 1:55 PM A. Antidiabetic Agents K. Sentena (OSU)
- 1. Non-insulin Class Update/Prior Authorization Criteria
 - 2. Insulin Class Update with DERP Summary/Prior Authorization Criteria
 - 3. Public Comment
 - 4. Discussion of Clinical Recommendations to OHA

- 2:35 PM B. Hepatitis C Class Update M. Herink (OSU)
- 1. Class Update/Prior Authorization Criteria
 - 2. Mavyret™ (glecaprevir/pibrentasvir) New Drug Evaluation
 - 3. Vosevi™ (sofosbuvir/velpatasvir/voxilaprevir) New Drug Evaluation
 - 4. Public Comment
 - 5. Discussion of Clinical Recommendations to OHA

3:15 PM BREAK

- 3:25 PM C. ADHD Class Update S. Servid (OSU)
- 1. Class Update/Prior Authorization Criteria
 - 2. Public Comment
 - 3. Discussion of Clinical Recommendations to OHA

- 3:35 PM D. Literature Scans
- 1. Antipsychotics, Parenteral
 - 2. Growth Hormones
 - 3. Newer Antiemetics
 - 4. Pancreatic Enzymes
 - 5. Platelet Inhibitors
 - 6. Topical Steroids
 - 7. Topical Antipsoriatics
 - 8. Public Comment
 - 9. Discussion of Clinical Recommendations to OHA
- D. Moretz (OSU)
D. Engen (OSU)
K. Sentena (OSU)
M. Herink (OSU)

4:05 PM V. EXECUTIVE SESSION

4:50 PM VI. RECONVENE for PUBLIC RECOMMENDATIONS

5:00 PM VII. ADJOURN